Elekta

56.80 SEK

+1.70 %

Less than 1K followers

EKTA B

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+1.70 %

+22.10 %

+28.22 %

+13.69 %

-7.11 %

-8.90 %

-8.21 %

-48.18 %

+551.12 %

Elekta operates in the medical technology industry and focuses on the development, manufacture and distribution of medical equipment for cancer treatment and neurosurgery. The company's products include radiotherapy machines and diagnostic imaging systems. The business has a global market position. Elekta was founded in 1972 and is headquartered in Stockholm.

Market cap

21.79B SEK

Turnover

58.28M SEK

Revenue

18.02B

EBIT %

4.94 %

P/E

91.61

Dividend yield-%

4.23 %

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

5.3

2026

Interim report Q3'26

5.3

2026

Half year dividend

28.5

2026

Annual report '26

All

Press releases

ShowingAll content types

Regulatory press release11/26/2025, 6:30 AM

Second quarter, August–October 2025/26

Press release11/12/2025, 6:30 AM

Invitation to the presentation of Elekta’s second quarter 2025/26

Regulatory press release10/31/2025, 6:30 AM

Elekta’s Nomination Committee for the Annual General Meeting 2026

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release10/9/2025, 5:30 AM

New impact report reveals radiotherapy’s role in cancer care

Press release9/29/2025, 6:10 PM

Study shows MRI-guided adaptive radiotherapy with Elekta Unity improves patient-reported urinary symptoms in men with prostate cancer

Press release9/25/2025, 5:30 AM

Elekta marks two millionth patient treated with Leksell Gamma Knife radiosurgery

Regulatory press release9/8/2025, 5:30 AM

Elekta announces changes in Executive Management

Regulatory press release9/4/2025, 2:56 PM

Report from the Annual General Meeting 2025 of Elekta

Regulatory press release8/28/2025, 5:30 AM

Interim report, First quarter May–July 2025/26

Press release8/7/2025, 5:30 AM

Invitation to the presentation of Elekta’s first quarter 2025/26

Regulatory press release8/1/2025, 5:30 AM

Notice to the Annual General Meeting of Elekta AB (Publ)

Press release7/23/2025, 1:00 PM

Elekta receives U.S. FDA 510(k) clearance for its Gamma Knife radiosurgery system to treat patients with refractory, drug-resistant mesial temporal lobe epilepsy

Regulatory press release7/4/2025, 11:30 AM

Elekta's Annual Report for 2024/25 available

Press release6/12/2025, 5:30 AM

Nomination Committee’s proposal for the Board of Directors prior to Elekta’s Annual General Meeting 2025

Press release6/10/2025, 9:00 AM

Elekta leaders present retrospective and future developments to investor community

Regulatory press release6/9/2025, 5:00 PM

Elekta appoints Jakob Just-Bomholt as new President and CEO

Press release6/5/2025, 5:30 AM

Elekta to enhance cancer treatment in Croatia through strategic acquisition

Regulatory press release5/28/2025, 5:30 AM

Year-end report May–April 2024/25

Press release5/13/2025, 5:30 AM

Invitation to the presentation of Elekta’s fiscal year 2024/25

Press release5/3/2025, 1:45 PM

Clinical trial shows more precise radiotherapy using Elekta Unity MR-Linac preserves sexual function in men with prostate cancer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.